Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Med Genomics ; 11(1): 80, 2018 Sep 20.
Article in English | MEDLINE | ID: mdl-30236106

ABSTRACT

BACKGROUND: The transition from ductal carcinoma in situ (DCIS) to invasive breast carcinoma (IBC) is an important step during breast carcinogenesis. Understanding its molecular changes may help to identify high-risk DCIS that progress to IBC. Here, we describe a transcriptomic profiling analysis of matched formalin-fixed and paraffin-embedded (FFPE) DCIS and IBC components of individual breast tumours, containing both tumour compartments. The study was performed to validate progression-associated transcripts detected in an earlier gene profiling project using fresh frozen breast cancer tissue. In addition, FFPE tissues from patients with pure DCIS (pDCIS) were analysed to identify candidate transcripts characterizing DCIS with a high or low risk of progressing to IBC. METHODS: Fifteen laser microdissected pairs of DCIS and IBC were profiled by Illumina DASL technology and used for expression validation by qPCR. Differential expression was independently validated using further 25 laser microdissected DCIS/IBC sample pairs. Additionally, laser microdissected epithelial cells from 31 pDCIS were investigated for expression of candidate transcripts using qPCR. RESULTS: Multiple statistical calculation methods revealed 1784 mRNAs which are differentially expressed between DCIS and IBC (P < 0.05), of which 124 have also been identified in the gene profiling project using fresh frozen breast cancer tissue. Nine mRNAs that had been selected from the gene list obtained using fresh frozen tissues by applying pathway and network analysis (MMP11, GREM1, PLEKHC1, SULF1, THBS2, CSPG2, COL10A1, COL11A1, KRT14) were investigated in tissues from the same 15 microdissected specimens and the 25 independent tissue samples by qPCR. All selected transcripts were also detected in tumour cells from pDCIS. Expression of MMP11 and COL10A1 increased significantly from pDCIS to DCIS of DCIS/IBC mixed tumours. CONCLUSION: We confirm differential expression of progression-associated transcripts in FFPE breast cancer samples which might mediate the transition from DCIS to IBC. MMP11 and COL10A1 may characterize pure DCIS with a high risk developing IDC.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Intraductal, Noninfiltrating/pathology , Gene Expression Regulation, Neoplastic , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Intraductal, Noninfiltrating/genetics , Carcinoma, Intraductal, Noninfiltrating/metabolism , Disease Progression , Female , Formaldehyde/chemistry , Gene Regulatory Networks , Humans , Paraffin Embedding , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction
2.
Mod Pathol ; 27(1): 19-29, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23807778

ABSTRACT

Adult-onset urticaria pigmentosa/mastocytosis in the skin almost always persists throughout life. The prevalence of systemic mastocytosis in such patients is not precisely known. Bone marrow biopsies from 59 patients with mastocytosis in the skin and all available skin biopsies (n=27) were subjected to a meticulous cytological, histological, immunohistochemical, and molecular analysis for the presence of WHO-defined diagnostic criteria for systemic mastocytosis: compact mast cell infiltrates (major criterion); atypical mast cell morphology, KIT D816V, abnormal expression of CD25 by mast cells, and serum tryptase levels >20 ng/ml (minor criteria). Systemic mastocytosis is diagnosed when the major diagnostic criterion plus one minor criterion or at least three minor criteria are fulfilled. Systemic mastocytosis was confirmed in 57 patients (97%) by the diagnosis of compact mast cell infiltrates plus at least one minor diagnostic criterion (n=42, 71%) or at least three minor diagnostic criteria (n=15, 25%). In two patients, only two minor diagnostic criteria were detectable, insufficient for the diagnosis of systemic mastocytosis. By the use of highly sensitive molecular methods, including the analysis of microdissected mast cells, KIT D816V was found in all 58 bone marrow biopsies investigated for it but only in 74% (20/27) of the skin biopsies. It is important to state that even in cases with insufficient diagnostic criteria for systemic mastocytosis, KIT D816V-positive mast cells were detected in the bone marrow. This study demonstrates, for the first time, that almost all patients with adult-onset mastocytosis in the skin, in fact, have systemic mastocytosis with cutaneous involvement.


Subject(s)
Mast Cells , Mastocytoma, Skin/diagnosis , Mastocytosis, Systemic/diagnosis , Skin , Adolescent , Adult , Age of Onset , Biomarkers/analysis , Biomarkers/blood , Biopsy , Bone Marrow Examination , DNA Mutational Analysis , Female , Humans , Immunohistochemistry , Interleukin-2 Receptor alpha Subunit/analysis , Male , Mast Cells/chemistry , Mast Cells/pathology , Mastocytoma, Skin/blood , Mastocytoma, Skin/chemistry , Mastocytoma, Skin/genetics , Mastocytoma, Skin/pathology , Mastocytosis, Systemic/blood , Mastocytosis, Systemic/genetics , Mastocytosis, Systemic/metabolism , Mastocytosis, Systemic/pathology , Microdissection , Middle Aged , Mutation , Predictive Value of Tests , Proto-Oncogene Proteins c-kit/genetics , Skin/chemistry , Skin/pathology , Tryptases/blood , Young Adult
3.
Mod Pathol ; 24(4): 585-95, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21186345

ABSTRACT

Systemic mastocytosis either presents as aggressive neoplasm with short survival time or indolent systemic mastocytosis with normal life expectancy. In both instances, neoplastic mast cells usually harbor the D816V-mutated variant of KIT. Phenotypically, mast cells in systemic mastocytosis usually express CD25. However, no robust marker that discriminates between aggressive and indolent variants of systemic mastocytosis has been identified yet. We here report that CD30, also known as Ki-1 antigen, is expressed in neoplastic mast cells in a majority of patients with advanced systemic mastocytosis (11/13, 85%), whereas in most patients with indolent systemic mastocytosis (12/45, 27%; P<0.001), only a few if any mast cells stained positive for CD30. These results could be confirmed by TissueFAXS analysis in subsets of patients with indolent systemic mastocytosis (n=7) and advanced systemic mastocytosis (n=4; P=0.008). The mast cell leukemia cell line HMC-1, derived from a patient with aggressive systemic mastocytosis also expressed the CD30 protein. In addition, we were able to detect CD30 mRNA in HMC-1 cells as well as in bone marrow biopsy samples in patients with systemic mastocytosis. In contrast, CD30 transcripts could not be detected in bone marrow biopsies in cases of reactive mast cell hyperplasia and in various other myeloid neoplasms. In conclusion, CD30 is preferentially expressed in neoplastic mast cells in advanced mast cell neoplasms. Upregulated expression of CD30 in advanced systemic mastocytosis may thus be employed as a potential marker for grading systemic mastocytosis in hematopathology.


Subject(s)
Biomarkers, Tumor/analysis , Ki-1 Antigen/analysis , Mast Cells/immunology , Mastocytosis, Systemic/immunology , Adult , Aged , Biomarkers, Tumor/genetics , Biopsy , Bone Marrow/immunology , Bone Marrow/pathology , Bone Marrow Examination , DNA Mutational Analysis , Female , Humans , Immunohistochemistry , Ki-1 Antigen/genetics , Male , Mast Cells/pathology , Mastocytosis, Systemic/genetics , Mastocytosis, Systemic/pathology , Middle Aged , Mutation , Prognosis , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation , Young Adult
4.
Nucleic Acids Res ; 36(7): e39, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18344524

ABSTRACT

Only few selected cancer cells drive tumor progression and are responsible for therapy resistance. Their specific genomic characteristics, however, are largely unknown because high-resolution genome analysis is currently limited to DNA pooled from many cells. Here, we describe a protocol for array comparative genomic hybridization (array CGH), which enables the detection of DNA copy number changes in single cells. Combining a PCR-based whole genome amplification method with arrays of highly purified BAC clones we could accurately determine known chromosomal changes such as trisomy 21 in single leukocytes as well as complex genomic imbalances of single cell line cells. In single T47D cells aberrant regions as small as 1-2 Mb were identified in most cases when compared to non-amplified DNA from 10(6) cells. Most importantly, in single micrometastatic cancer cells isolated from bone marrow of breast cancer patients, we retrieved and confirmed amplifications as small as 4.4 and 5 Mb. Thus, high-resolution genome analysis of single metastatic precursor cells is now possible and may be used for the identification of novel therapy target genes.


Subject(s)
DNA, Neoplasm/analysis , Neoplasm Metastasis/genetics , Neoplastic Stem Cells/chemistry , Oligonucleotide Array Sequence Analysis/methods , Breast Neoplasms/pathology , Cell Line, Tumor , Chromosomes, Artificial, Bacterial , DNA, Bacterial/analysis , DNA, Bacterial/isolation & purification , Female , Gene Dosage , Genomics/methods , Humans , Male , Polymerase Chain Reaction
5.
Curr Protoc Hum Genet ; Chapter 11: Unit 11.8, 2005 Feb.
Article in English | MEDLINE | ID: mdl-18428372

ABSTRACT

The need to analyze rare cells is based on the nature of tissue differentiation and regeneration, the initiation and propagation of disease processes in multicellular organisms, and the functional diversity of individual cells. Gene transcription is the most important regulatory mechanism by which a phenotype and functional state of a cell is determined. Therefore, procedures for the qualitative and quantitative assessment of mRNA abundance are important. This unit presents a protocol for semi-quantitative analysis of gene expression of a single cell and quantitative representation of expressed genes from >10 to 30 cells. A basic protocol for array hybridization on nylon filters is provided because such filters are available in every laboratory. Tissue samples contain many different cell types in variable amounts, so their analysis may require microdissection; a protocol for obtaining cryosections is given. Finally, a simple procedure to prepare the data for statistical analysis is also provided.


Subject(s)
Gene Expression Profiling , Base Sequence , DNA, Complementary/genetics , Humans
6.
Curr Protoc Mol Biol ; Chapter 25: Unit 25B.8, 2003 Feb.
Article in English | MEDLINE | ID: mdl-18265324

ABSTRACT

The need to analyze rare cells is based on the nature of tissue differentiation and regeneration, the initiation and propagation of disease processes in multicellular organisms, and the functional diversity of individual cells. Gene transcription is the most important regulatory mechanism by which a phenotype and functional state of a cell is determined. Therefore, procedures for the qualitative and quantitative assessment of mRNA abundance are important. This unit presents a protocol for semi-quantitative analysis of gene expression of a single cell and quantitative representation of expressed genes from >10 to 30 cells. A basic protocol for array hybridization on nylon filters is provided because such filters are available in every laboratory. Tissue samples contain many different cell types in variable amounts, so their analysis may require microdissection; a protocol for obtaining cryosections is given. Finally, a simple procedure to prepare the data for statistical analysis is also provided.


Subject(s)
Cells/metabolism , Gene Expression Profiling/methods , Polymerase Chain Reaction/methods , Animals , Binding Sites , Biopsy , Calibration , DNA Primers , DNA, Complementary/genetics , Indicators and Reagents , Microdissection , Oligodeoxyribonucleotides , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , RNA, Messenger/isolation & purification
7.
Nat Biotechnol ; 20(4): 387-92, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11923846

ABSTRACT

In human cancer, early systemic spread of tumor cells is recognized as a leading cause of death. Adjuvant therapies are administered to patients after complete resectioning of their primary tumors to eradicate the few residual and latent metastatic cells. These therapeutic regimens, however, are currently designed without direct information about the presence or nature of the latent cells. To address this problem, we developed a PCR-based technique to analyze the transcriptome of individual tumor cells isolated from the bone marrow of cancer patients. From the same cells, genomic aberrations were identified by comparative genomic hybridization. The utility of this approach for understanding the biology of occult disseminated cells and for the identification of new therapeutic targets is demonstrated here by the detection of frequent extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) expression which was verified by immunostaining.


Subject(s)
Gene Expression Profiling/methods , Genome, Human , Genomics/methods , Neoplasm Metastasis/genetics , Oligonucleotide Array Sequence Analysis/methods , Transcription, Genetic/genetics , Cell Cycle/genetics , Humans , Neoplasm Metastasis/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...